MYH9 and nasopharyngeal carcinoma: Furthermore, we observed that the half-life of GSK3β did not change when cells were treated with a reversible proteasome inhibitor, MG132 (Fig. 4d); however, the half-life of β-catenin was prolonged in MYH9-overexpressing NPC cells compared to the control group (Fig. 4e).